NasdaqGS:LXRX

Stock Analysis Report

Executive Summary

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products.

Snowflake

Fundamentals

High growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has Lexicon Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-9.0%

LXRX

0.8%

US Biotechs

1.0%

US Market


1 Year Return

-62.0%

LXRX

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: LXRX underperformed the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: LXRX underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

LXRXIndustryMarket
7 Day-9.0%0.8%1.0%
30 Day38.5%-3.9%-1.8%
90 Day-41.5%-3.5%-1.8%
1 Year-62.0%-62.0%-7.5%-8.3%9.1%6.7%
3 Year-80.4%-80.4%13.6%9.6%46.1%36.6%
5 Year-64.9%-64.9%3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is Lexicon Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lexicon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Lexicon Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexicon Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

48.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LXRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: LXRX is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: LXRX's loss is forecast to worsen by 0% next year.

Revenue vs Market: LXRX's revenue (22.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: LXRX's revenue (22.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if LXRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Lexicon Pharmaceuticals performed over the past 5 years?

-8.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: LXRX is unprofitable, and losses have increased over the past 5 years at a rate of -8.6% per year.

Accelerating Growth: Unable to compare LXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LXRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: LXRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: LXRX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LXRX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Lexicon Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: LXRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LXRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LXRX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LXRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: LXRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: LXRX has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LXRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LXRX has sufficient cash runway for 1.448070 years if free cash flow continues to reduce at historical rates of -32.6% each year.


Next Steps

Dividend

What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Lexicon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

7.3yrs

Average management tenure


CEO

Lonnel Coats (54yo)

5.3yrs

Tenure

US$3,123,433

Compensation

Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei ...


CEO Compensation Analysis

Compensation vs. Market: Lonnel's total compensation ($USD3.12M) is above average for companies of similar size in the US market ($USD1.85M).

Compensation vs Earnings: Lonnel's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

7.3yrs

Average Tenure

59yo

Average Age

Experienced Management: LXRX's management team is seasoned and experienced (7.3 years average tenure).


Board Age and Tenure

12.2yrs

Average Tenure

64yo

Average Age

Experienced Board: LXRX's board of directors are seasoned and experienced ( 12.2 years average tenure).


Insider Trading

Insider Buying: LXRX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$155,00019 Sep 19
Lonnel Coats
EntityIndividual
Role
Chief Executive Officer
President
Shares50,000
Max PriceUS$3.10
BuyUS$15,11519 Sep 19
Alexander Santini
EntityIndividual
Role
Senior Key Executive
Executive VP & Chief Commercial Officer
Shares4,500
Max PriceUS$3.52
BuyUS$156,40318 Sep 19
Lonnel Coats
EntityIndividual
Role
Chief Executive Officer
President
Shares50,000
Max PriceUS$3.13
BuyUS$752,35117 Sep 19
Raymond Debbane
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares300,515
Max PriceUS$2.80
BuyUS$302,46817 Sep 19
Christopher Sobecki
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares124,249
Max PriceUS$2.75
BuyUS$54,02920 Aug 19
Lonnel Coats
EntityIndividual
Role
Chief Executive Officer
President
Shares40,000
Max PriceUS$1.40
BuyUS$11,40002 Aug 19
James Tessmer
EntityIndividual
Role
Chief Accounting Officer
Vice President of Finance & Accounting
Shares10,000
Max PriceUS$1.14
BuyUS$28,20002 Aug 19
Samuel Barker
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares24,000
Max PriceUS$1.18

Ownership Breakdown


Management Team

  • Jeffrey Wade (54yo)

    Executive VP of Corporate & Administrative Affairs and CFO

    • Tenure: 9.4yrs
    • Compensation: US$1.41m
  • Robert Lefkowitz (75yo)

    Consultant & Director

    • Tenure: 18.7yrs
    • Compensation: US$96.22k
  • Praveen Tyle (59yo)

    Executive Vice President of Research & Development

    • Tenure: 3.4yrs
    • Compensation: US$1.46m
  • Lonnel Coats (54yo)

    President

    • Tenure: 5.3yrs
    • Compensation: US$3.12m
  • James Tessmer (59yo)

    Vice President of Finance & Accounting

    • Tenure: 11.9yrs
    • Compensation: US$508.34k
  • Pablo Lapuerta (56yo)

    Executive VP & Chief Medical Officer

    • Tenure: 4.7yrs
    • Compensation: US$1.26m
  • Brian Crum

    Vice President

    • Tenure: 0yrs
  • Chas Schultz

    Executive Director of Corporate Communications & Patient Advocacy

    • Tenure: 18.8yrs
  • Alex Santini (60yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 2.9yrs
    • Compensation: US$1.23m
  • Kimberly Lee

    Head of Investor Relations & Corporate Strategy

    • Tenure: 0yrs

Board Members

  • Ray Debbane (64yo)

    Independent Chairman of the Board

    • Tenure: 7.7yrs
    • Compensation: US$80.39k
  • Sam Barker (76yo)

    Independent Director

    • Tenure: 19.6yrs
    • Compensation: US$69.39k
  • Philippe Amouyal (60yo)

    Independent Director

    • Tenure: 12.2yrs
    • Compensation: US$63.89k
  • Robert Lefkowitz (75yo)

    Consultant & Director

    • Tenure: 18.7yrs
    • Compensation: US$96.22k
  • Christopher Sobecki (60yo)

    Independent Director

    • Tenure: 12.2yrs
    • Compensation: US$60.39k
  • Judith Swain (70yo)

    Independent Director

    • Tenure: 12.1yrs
    • Compensation: US$65.89k
  • Alan Nies (81yo)

    Chairman of Medical Advisory Board & Independent Director

    • Tenure: 16.6yrs
    • Compensation: US$137.05k
  • Frank Palantoni (62yo)

    Independent Director

    • Tenure: 14.9yrs
    • Compensation: US$69.39k
  • Lonnel Coats (54yo)

    President

    • Tenure: 5.3yrs
    • Compensation: US$3.12m

Company Information

Lexicon Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lexicon Pharmaceuticals, Inc.
  • Ticker: LXRX
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$344.321m
  • Shares outstanding: 106.27m
  • Website: https://www.lexpharma.com

Number of Employees


Location

  • Lexicon Pharmaceuticals, Inc.
  • 8800 Technology Forest Place
  • The Woodlands
  • Texas
  • 77381
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LXRXNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDApr 2000
LX31DB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2000
LX31MUN (Boerse Muenchen)YesCommon SharesDEEURApr 2000

Biography

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:36
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.